|
| Marker | Cancer | Anticancer therapy | Correlation | Reference |
|
| Left atrial enlargement | HER2-positive breast cancer | Trastuzumab (TZ) therapy | LA dilatation associated with the development of cardiotoxicity | Corinna Bergamini |
| Breast cancer | Anthracycline therapy | Maximum LA volume significantly increased in the patients | Yalin Tolga Yaylal |
| Solid cancer (gynecological, breast, gastrointestinal, sarcoma, lungs) | Therapy-naive | LA reservoir and conduit functions were deteriorated in the cancer group | Marijana Tadic |
| Breast cancer | Chemotherapy and trastuzumab therapy | Left atrial longitudinal strain as a predictor of cancer therapeutics-related cardiac dysfunction | Hyukjin Park |
|
| ECG abnormalities | Breast cancer | Anthracycline therapy | Left intraatrial and interatrial electromechanical intervals were prolonged | Yalin Tolga Yaylal |
| Chronic lymphocytic leukemia (CLL) | Ibrutinib | Left atrial abnormality identified by EKG can identify patients at increased risk for this toxicity. | |
| Multiple cancer | Cardiac-directed radiation; anthracycline and/or alkylating chemotherapies | ECG abnormalities are common among childhood cancer survivors and predictive of both cardiac and all-cause mortality | Daniel A. Mulrooney |
| Left atrial myxoma | Tumor excision | Increased PTFV1 correlates with the tumor size | Norihiro Komiya |
|
| NT-proBNP | Coronary artery disease free of cancer | — | NT-proBNP is an independent predictor of malignancies in patients with CAD | José Tuñón |
| Neuroendocrine tumor (NET) | — | NT-proBNP are important markers in the diagnosis and survival | Catharina M. Korse |
| Multiple myeloma (MM) | Chemotherapy | Elevated levels of NT-proBNP are associated with disease severity | Noemi Pavo |
| Differentiated thyroid carcinoma | Total thyroidectomy and radioiodine ablation | NT-proBNP associated with an increased risk for cardiovascular events and all-cause mortality | Esther N. Klein Hesselink |
| Cancer | — | BNP levels are elevated and an indicator of heart failure | Sachiko Bando |
| Breast cancer | Not-high-dose chemotherapy | NT-proBNP detects high risk of developing cardiotoxicity | S. Romano |
| Non-Hodgkin lymphoma | Chemotherapy | NT-proBNP is a marker for risk assessment for NHL patients | Eva Gimeno |
| Metastatic renal cell carcinoma | Sunitinib | NT-proBNP predicts for clinical benefit to sunitinib treatment | Konstantinos T. Papazisis |
|
